Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non–muscle-invasive Bladder Cancer

European Urology Oncology(2025)10.1016/j.euo.2025.04.006Source: DataRank Database

Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non–muscle-invasive Bladder Cancer is a research paper published in European Urology Oncology (2025). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 8.02)OA: hybridTopics (54)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Ian M. McElree ORCID,Saum Ghodoussipour ORCID,Vivek Nimgaonkar,Viswesh Krishna ORCID,Joon Kyung Kim ORCID

Live enrichment

PubMed:40287344 OpenAlex:https://openalex.org/W4409795178

Markey Cancer Center, University of Kentucky

Grant: P30CA177558

NCI NIH HHS

Grant: P30 CA072720

NCI NIH HHS

Grant: P30 CA086862

FWCI

8.02

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.euo.2025.04.006

publisherhttps://doi.org/10.1016/j.euo.2025.04.006

publisherhttps://api.elsevier.com/content/article/PII:S2588931125001002?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2588931125001002?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40287344

Fields of Study

Bladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesColorectal Cancer Screening and DetectionHumansUrinary Bladder NeoplasmsGemcitabineDeoxycytidineFemaleMaleBCG VaccineAgedDocetaxelArtificial IntelligenceMiddle AgedAdministration, IntravesicalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorNeoplasm GradingNeoplasm InvasivenessAdjuvants, ImmunologicAged, 80 and overNon-Muscle Invasive Bladder Neoplasms

MeSH Terms

DocetaxelNon-Muscle Invasive Bladder NeoplasmsGemcitabineAdjuvants, ImmunologicAdministration, IntravesicalAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsArtificial IntelligenceBCG VaccineUrinary Bladder NeoplasmsDeoxycytidineFemaleHumansMaleMiddle AgedNeoplasm InvasivenessBiomarkers, TumorNeoplasm Grading

Keywords

GemcitabineMedicineDocetaxelBiomarkerBladder cancerOncologyInternal medicineUrologyCancerArtificial intelligenceBacillus Calmette-GuerinMachine learningNon–muscle-invasive bladder cancer

Sustainable Development Goals

SDG 0: No poverty